IN THIS ISSUE

Highlighted research articles ...................................... 705

NEWS IN BRIEF

Important news stories affecting the community ................. 709

NEWS IN DEPTH

Q&A: Suzanne Topalian on Immune Therapies .................. 712
A Look at the Origins of Cancer Epigenetics ..................... 713

RESEARCH WATCH

Selected highlights of recent articles of exceptional significance from the cancer literature ............. 714

ONLINE

For more News and Research Watch, visit Cancer Discovery online at http://CDnews.aacrjournals.org.

REVIEW

Oncogenic Isocitrate Dehydrogenase Mutations: Mechanisms, Models, and Clinical Opportunities .......... 730
R.A. Cairns and T.W. Mak

RESEARCH BRIEFS

Discovery of a Novel ERK Inhibitor with Activity in Models of Acquired Resistance to BRAF and MEK Inhibitors .......... 742
Précis: An ERK1/2 inhibitor with properties of both type I and type II kinase inhibitors suppresses MAPK signaling and proliferation in BRAF and MEK inhibitor-resistant cancer cells. See commentary, p. 719

Inhibition of Ron Kinase Blocks Conversion of Micrometastases to Overt Metastases by Boosting Antitumor Immunity .............. 751
H. Eyob, H.A. Ekiz, Y.S. DeRose, S.E. Waltz, M.A. Williams, and A.L. Welm
Précis: The receptor tyrosine kinase RON suppresses antitumor immune responses to promote metastatic outgrowth and is a potential therapeutic target to inhibit metastasis.

Frequent Mutation of the PI3K Pathway in Head and Neck Cancer Defines Predictive Biomarkers ... 761
Précis: PI3K pathway mutations are found in 30.5% of head and neck squamous cell carcinomas and may indicate sensitivity to PI3K inhibitors. See commentary, p. 722

Q&A: Suzanne Topalian on Immune Therapies .................. 712
H. Eyob, H.A. Ekiz, Y.S. DeRose, S.E. Waltz, M.A. Williams, and A.L. Welm
Précis: An ERK1/2 inhibitor with properties of both type I and type II kinase inhibitors suppresses MAPK signaling and proliferation in BRAF and MEK inhibitor-resistant cancer cells. See commentary, p. 719

Inhibition of Ron Kinase Blocks Conversion of Micrometastases to Overt Metastases by Boosting Antitumor Immunity .............. 751
H. Eyob, H.A. Ekiz, Y.S. DeRose, S.E. Waltz, M.A. Williams, and A.L. Welm
Précis: The receptor tyrosine kinase RON suppresses antitumor immune responses to promote metastatic outgrowth and is a potential therapeutic target to inhibit metastasis.

Frequent Mutation of the PI3K Pathway in Head and Neck Cancer Defines Predictive Biomarkers ... 761
Précis: PI3K pathway mutations are found in 30.5% of head and neck squamous cell carcinomas and may indicate sensitivity to PI3K inhibitors. See commentary, p. 722

In The Spotlight

ERK Pathway Inhibitors: How Low Should We Go? ............ 719
M.H. Nissan, N. Rosen, and D.B. Solit
See article, p. 742

Exploiting the Head and Neck Cancer Oncogenome: Widespread PI3K-mTOR Pathway Alterations and Novel Molecular Targets ........ 722
R. Iglesias-Bartolome, D. Martin, and J.S. Gutkind
See article, p. 761
See article, p. 770

Not Expecting the Unexpected: Diacylglycerol Kinase Alpha as a Cancer Target ....................... 726
K.P.L. Bhat and K. Aldape
See article, p. 782

Scanning for Clues to Better Use Selective Estrogen Receptor Modulators .................... 728
M.J. Machiela and S.J. Chanock
See article, p. 812

In The Spotlight

ERK Pathway Inhibitors: How Low Should We Go? ............ 719
M.H. Nissan, N. Rosen, and D.B. Solit
See article, p. 742

Exploiting the Head and Neck Cancer Oncogenome: Widespread PI3K-mTOR Pathway Alterations and Novel Molecular Targets ........ 722
R. Iglesias-Bartolome, D. Martin, and J.S. Gutkind
See article, p. 761
See article, p. 770

Not Expecting the Unexpected: Diacylglycerol Kinase Alpha as a Cancer Target ....................... 726
K.P.L. Bhat and K. Aldape
See article, p. 782

Scanning for Clues to Better Use Selective Estrogen Receptor Modulators .................... 728
M.J. Machiela and S.J. Chanock
See article, p. 812

Précis: Gene expression, copy number, methylation, and mutation analyses implicate Notch deregulation in oral squamous cell carcinoma and identify potentially actionable events.

See commentary, p. 722


Précis: Inhibition of diacylglycerol kinase α downregulates oncogenic pathways including HIF-1α and mTOR and is selectively toxic to glioblastoma and other cancer cells.

See commentary, p. 726


Précis: ZNF365 is a p53-inducible gene product that maintains genomic stability by preventing recombination of defective telomere ends and common fragile site abnormalities.


Précis: SNPs related to ZNF423 and CTSO are associated with breast cancer risk during SERM therapy, and these genes promote estrogen-dependent induction of BRCA1 transcription in an SNP-dependent fashion.

See commentary, p. 728

For more News and Research Watch, visit Cancer Discovery online at http://CDnews.aacrjournals.org. Online-only News stories include the following:

- PI3K-δ Inhibitor Produces Long-Lasting Responses
- Price Breaks for HPV Vaccines May Aid Prevention
- Olaparib Shows Promise in Multiple Tumor Types
- New Risk Factors for Testicular Cancer
- Benchtop Sequencers Find a New Home
- Ganetespib Aids Lung Cancer Survival

AC icon indicates Author Choice

For more information please visit http://www.aacrjournals.org

Head and neck squamous cell carcinomas (HNSCC) are a genetically heterogeneous group of cancers with a poor survival rate. Lui and colleagues evaluated the mutation frequency of mitogenic pathways in HNSCCs and found that 30.5% of tumors harbored PI3K pathway mutations. Patient-derived tumorgrafts with hotspot and noncanonical PIK3CA mutations were highly sensitive to PI3K inhibitors. Pickering and colleagues performed integrated genomic analyses of oral squamous cell carcinomas (OSCC), a particularly lethal, poorly characterized HNSCC subtype. The Notch pathway was deregulated in 66% of OSCCs, and inactivation of NOTCH1 was shown to drive OSCC growth. Common inactivating mutations of FAT1 and CASP8 were also identified. Together, these findings provide insight into the etiology of HNSCC and identify potential therapeutic targets. For details, please see the article by Lui and colleagues on page 761 and the article by Pickering and colleagues on page 770.